Drug intelligence / Profile preview

detorsertib

Development stage: Phase 1
Lead developer: Kintor Pharmaceutical
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Oral

Overview

Detorsertib (GT0486) is a novel small molecule dual inhibitor targeting both mTORC1 and mTORC2 complexes. It selectively suppresses mTOR kinase activity and has demonstrated potent antitumor efficacy in preclinical models. Detorsertib is being developed by Suzhou Kintor Pharmaceuticals for the treatment of advanced solid tumors, including metastatic disease. The drug has shown synergistic effects when combined with BTK inhibitors in preclinical studies and is currently undergoing Phase I clinical trials in China for solid tumors[3][4][5][6].

Other names: detorsertibGT0486GT-0486GT 0486

Targets

Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2

Beyond the preview

Go deeper on detorsertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on detorsertib.